Heit JA (2005) Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3(8):1611–1617. https://doi.org/10.1111/j.1538-7836.2005.01415.x

Article  CAS  PubMed  Google Scholar 

Di Nisio M, van Es N, Büller HR (2016) Deep vein thrombosis and pulmonary embolism. Lancet 388(10063):3060–3073. https://doi.org/10.1016/S0140-6736(16)30514-1

Article  PubMed  Google Scholar 

WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, et al (2010) Heart disease and stroke statistics--2010 update: a report from the American Heart Association [published correction appears in Circulation. 2010 Mar 30;121(12):e260. Stafford, Randall [corrected to Roger, Véronique L]] [published correction appears in Circulation. 2011 Oct 18;124(16):e425]. Circulation 121(7):e46–e215. doi:https://doi.org/10.1161/CIRCULATIONAHA.109.192667

Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808. https://doi.org/10.1056/NEJMoa1302507

Article  CAS  PubMed  Google Scholar 

EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510. doi:https://doi.org/10.1056/NEJMoa1007903

Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report [published correction appears in Chest. 2016 Oct;150(4):988]. Chest 149(2):315–352. doi:https://doi.org/10.1016/j.chest.2015.11.026

Konstantinides SV, Meyer G, Becattini C et al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405

Article  PubMed  Google Scholar 

Ortel TL, Neumann I, Ageno W et al (2020) American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 4(19):4693–4738. https://doi.org/10.1182/bloodadvances.2020001830

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sindet-Pedersen C, Pallisgaard JL, Staerk L, et al (2017) Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study. Sci Rep 7(1):3347. Published 2017 Jun 13. doi:https://doi.org/10.1038/s41598-017-03596-x

Kakkos SK, Kirkilesis GI, Tsolakis IA (2014) Editor’s Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 48(5):565–575. https://doi.org/10.1016/j.ejvs.2014.05.001

Article  CAS  PubMed  Google Scholar 

Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017–2023. https://doi.org/10.1200/JCO.2018.78.8034

Article  CAS  PubMed  Google Scholar 

Khorana AA, Noble S, Lee AYY et al (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891–1894. https://doi.org/10.1111/jth.14219

Article  CAS  PubMed  Google Scholar 

Agnelli G, Becattini C, Meyer G et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599–1607. https://doi.org/10.1056/NEJMoa1915103

Article  CAS  PubMed  Google Scholar 

Mantha S, Ansell J (2015) Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis 39(2):155–165. https://doi.org/10.1007/s11239-014-1102-5

Article  CAS  PubMed  Google Scholar 

Cohen AT, Hamilton M, Mitchell SA, et al (2015) Comparison of the novel oral anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One 10(12):e0144856. Published 2015 Dec 30. doi:https://doi.org/10.1371/journal.pone.0144856

Mamas MA, Batson S, Pollock KG et al (2022) Meta-analysis comparing Apixaban versus rivaroxaban for management of patients with nonvalvular atrial fibrillation. Am J Cardiol 166:58–64. https://doi.org/10.1016/j.amjcard.2021.11.021

Article  CAS  PubMed  Google Scholar 

Sterne JA, Hernán MA, Reeves BC, et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. Published 2016 Oct 12. doi:https://doi.org/10.1136/bmj.i4919

Schulman S, Kearon C (2005) Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694. doi:https://doi.org/10.1111/j.1538-7836.2005.01204.x

Higgins JPT, Cochrane Collaboration (2020) Cochrane handbook for systematic reviews of interventions, 2nd edn. Wiley-Blackwell, Hoboken

Brucks EB, Veeravelli S, Halder R et al (2020) Retrospective real-world analysis of the primary safety outcomes in venous thromboembolism of high-risk major bleeding cancer patients receiving therapeutic anticoagulation. Blood 136(Supplement 1):15–16. https://doi.org/10.1182/blood-2020-139641

Article  Google Scholar 

Davis DO, Davis KA (2018) Evaluation of direct-acting oral anticoagulant use in patients with cancer. J Pharm Pract 31(5):441–444. https://doi.org/10.1177/0897190017722873

Article  PubMed  Google Scholar 

Dawwas GK, Leonard CE, Lewis JD, Cuker A (2022) Risk for recurrent venous thromboembolism and bleeding with Apixaban compared with rivaroxaban: an analysis of real-world data [published correction appears in Ann Intern Med. 2022 Nov;175(11):1627–1628]. Ann Intern Med 175(1):20–28. doi:https://doi.org/10.7326/M21-0717

Dawwas GK, Brown J, Dietrich E, Park H (2019) Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol 6(1):e20–e28. https://doi.org/10.1016/S2352-3026(18)30191-1

Article  PubMed  Google Scholar 

Bott-Kitslaar DM, McBane RD, Casanegra AI et al (2019) Apixaban and rivaroxaban in patients with acute venous thromboembolism. Mayo Clin Proc 94(7):1242–1252. https://doi.org/10.1016/j.mayocp.2018.09.022

Article  CAS  PubMed  Google Scholar 

Kushnir M, Choi Y, Eisenberg R et al (2019) Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol 6(7):e359–e365. https://doi.org/10.1016/S2352-3026(19)30086-9

Article  PubMed  Google Scholar 

Sindet-Pedersen C, Staerk L, Pallisgaard JL et al (2018) Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. Eur Heart J Cardiovasc Pharmacother 4(4):220–227. https://doi.org/10.1093/ehjcvp/pvy021

Article  PubMed  Google Scholar 

Trujillo-Santos J, Beroiz P, Moustafa F (2020) Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism [published correction appears in Thromb Res. 2020 Dec; 196:641] [published correction appears in Thromb Res. et al 2021 Dec 208:233]. Thromb Res 193:160–165. https://doi.org/10.1016/j.thromres.2020.06.035

Article  CAS  PubMed  Google Scholar 

Wysokinski WE, Houghton DE, Casanegra AI et al (2019) Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol 94(11):1185–1192. https://doi.org/10.1002/ajh.25604

Article  CAS  PubMed  Google Scholar 

Aryal MR, Gosain R, Donato A et al (2019) Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv 3(15):2381–2387. https://doi.org/10.1182/bloodadvances.2019000572

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frost C, Song Y, Barrett YC, et al (2014) A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [published correction appears in Clin Pharmacol. 2018 Jun 11;10:71]. Clin Pharmacol 6:179–187. Published 2014 Nov 13. doi:https://doi.org/10.2147/CPAA.S61131

Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484–3488. https://doi.org/10.1182/blood-2002-01-0108

Article  CAS  PubMed  Google Scholar 

Key NS, Khorana AA, Kuderer NM et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496–520. https://doi.org/10.1200/JCO.19.01461

Article  PubMed  Google Scholar 

Brandão GMS, Malgor RD, Vieceli T et al (2022) A network meta-analysis of direct factor Xa inhibitors for the treatment of cancer-associated venous thromboembolism. Vascular 30(1):130–145. https://doi.org/10.1177/17085381211002726

Article  CAS  PubMed  Google Scholar